Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pixantrone (BBR 2778) Versus Other Chemotherapeutic Agents for Third-Line Single Agent Treatment of Patients With Relapsed Aggressive Non-Hodgkins Lymphoma: A Randomized, Controlled, Phase III Comparative Trial

Next Previous
X
Search
Trial Profile

Pixantrone (BBR 2778) Versus Other Chemotherapeutic Agents for Third-Line Single Agent Treatment of Patients With Relapsed Aggressive Non-Hodgkins Lymphoma: A Randomized, Controlled, Phase III Comparative Trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Oct 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pixantrone (Primary) ; Etoposide; Etoposide; Gemcitabine; Ifosfamide; Mitoxantrone; Oxaliplatin; Rituximab; Vinorelbine
  • Indications Anaplastic large cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms EXTEND
  • Sponsors CTI BioPharma

    • Most Recent Events

    • 13 Jun 2019 According to a Servier media release, the EC approval is based on data from the global clinical development of PIXUVRI which included pivotal study (PIX301) and a further Phase III clinical study (PIX306) conducted to satisfy requirements of the conditional authorization.
    • 13 Jun 2019 According to a Servier media release, the European Commission (EC) has approved the conversion of the conditional approval of PIXUVRI (pixantrone) into a standard marketing authorization as a single agent for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma.
    • 09 Apr 2019 According to a Servier media release, the positive opinion from the CHMP is based on data from the global clinical development of PIXUVRI which included pivotal study (PIX301) and a further Phase III clinical study (PIX306) conducted to satisfy requirements of the conditional authorization.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top